ASX - By Stock
|
RAC |
Re:
Ann: Bisantrene Phase 2 AML Trial Successful Concludes
|
|
EDTD
|
81 |
23K |
41 |
01/08/24 |
01/08/24 |
ASX - By Stock
|
81
|
23K
|
41
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Bisantrene Phase 2 AML Trial Successful Concludes
|
|
EDTD
|
81 |
23K |
30 |
01/08/24 |
01/08/24 |
ASX - By Stock
|
81
|
23K
|
30
|
|
ASX - By Stock
|
LPD |
Re:
Ann: Quarterly Activities/Appendix 5B Cash Flow Report
|
|
EDTD
|
79 |
22K |
8 |
01/08/24 |
01/08/24 |
ASX - By Stock
|
79
|
22K
|
8
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Bisantrene Phase 2 AML Trial Successful Concludes
|
|
EDTD
|
81 |
23K |
59 |
30/07/24 |
30/07/24 |
ASX - By Stock
|
81
|
23K
|
59
|
|
ASX - By Stock
|
LPD |
Re:
Managements Awkward Silence
|
|
EDTD
|
110 |
55K |
19 |
24/07/24 |
24/07/24 |
ASX - By Stock
|
110
|
55K
|
19
|
|
ASX - By Stock
|
NVA |
Re:
Ann: Nova Announces Pricing of US$3.3m NASDAQ IPO
|
|
EDTD
|
59 |
15K |
1 |
24/07/24 |
24/07/24 |
ASX - By Stock
|
59
|
15K
|
1
|
|
ASX - By Stock
|
RAC |
Re:
Q. Bisantrene is not new. How can RAC monetise if it is out of patent?
|
|
EDTD
|
391 |
84K |
13 |
11/07/24 |
11/07/24 |
ASX - By Stock
|
391
|
84K
|
13
|
|
ASX - By Stock
|
LPD |
Re:
General Discussion
|
|
EDTD
|
1.2K |
441K |
12 |
05/07/24 |
05/07/24 |
ASX - By Stock
|
1.2K
|
441K
|
12
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Race In-person Investor Briefing Invitation Perth
|
|
EDTD
|
130 |
39K |
49 |
04/07/24 |
04/07/24 |
ASX - By Stock
|
130
|
39K
|
49
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Race In-person Investor Briefing Invitation Perth
|
|
EDTD
|
130 |
39K |
29 |
04/07/24 |
04/07/24 |
ASX - By Stock
|
130
|
39K
|
29
|
|
ASX - By Stock
|
LPD |
Re:
General Discussion
|
|
EDTD
|
1.2K |
441K |
10 |
02/07/24 |
02/07/24 |
ASX - By Stock
|
1.2K
|
441K
|
10
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Race In-person Investor Briefing Invitation Perth
|
|
EDTD
|
130 |
39K |
12 |
02/07/24 |
02/07/24 |
ASX - By Stock
|
130
|
39K
|
12
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Race In-person Investor Briefing Invitation Perth
|
|
EDTD
|
130 |
39K |
17 |
02/07/24 |
02/07/24 |
ASX - By Stock
|
130
|
39K
|
17
|
|
ASX - By Stock
|
LPD |
Re:
Managements Awkward Silence
|
|
EDTD
|
110 |
55K |
11 |
28/06/24 |
28/06/24 |
ASX - By Stock
|
110
|
55K
|
11
|
|
ASX - By Stock
|
LPD |
Re:
Managements Awkward Silence
|
|
EDTD
|
110 |
55K |
7 |
28/06/24 |
28/06/24 |
ASX - By Stock
|
110
|
55K
|
7
|
|
ASX - By Stock
|
RAC |
Re:
Ann: RC220 GLP Non-clinical Toxicology Program Successful
|
|
EDTD
|
80 |
26K |
7 |
26/06/24 |
26/06/24 |
ASX - By Stock
|
80
|
26K
|
7
|
|
ASX - By Stock
|
RAC |
Re:
Ann: RC220 GLP Non-clinical Toxicology Program Successful
|
|
EDTD
|
80 |
26K |
12 |
26/06/24 |
26/06/24 |
ASX - By Stock
|
80
|
26K
|
12
|
|
ASX - By Stock
|
MSB |
Re:
banter and General Discussion
|
|
EDTD
|
11K |
3.5M |
7 |
25/06/24 |
25/06/24 |
ASX - By Stock
|
11K
|
3.5M
|
7
|
|
ASX - By Stock
|
MSB |
Re:
banter and General Discussion
|
|
EDTD
|
11K |
3.5M |
4 |
25/06/24 |
25/06/24 |
ASX - By Stock
|
11K
|
3.5M
|
4
|
|
ASX - By Stock
|
RAC |
Re:
Cardioprotection thread
|
|
EDTD
|
906 |
275K |
11 |
23/06/24 |
23/06/24 |
ASX - By Stock
|
906
|
275K
|
11
|
|
ASX - By Stock
|
LPD |
Re:
General Discussion
|
|
EDTD
|
1.2K |
441K |
25 |
19/06/24 |
19/06/24 |
ASX - By Stock
|
1.2K
|
441K
|
25
|
|
ASX - By Stock
|
RAC |
Re:
Ann: FDA RPD Designation Granted for RC220 Bisantrene
|
|
EDTD
|
80 |
26K |
18 |
18/06/24 |
18/06/24 |
ASX - By Stock
|
80
|
26K
|
18
|
|
ASX - By Stock
|
RAC Biotech |
Re:
RAC - Charts & Price Action
|
|
EDTD
|
22K |
7.9M |
18 |
07/06/24 |
07/06/24 |
ASX - By Stock
|
22K
|
7.9M
|
18
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Bonus Options Offer Results
|
|
EDTD
|
35 |
12K |
24 |
06/06/24 |
06/06/24 |
ASX - By Stock
|
35
|
12K
|
24
|
|
ASX - By Stock
|
CU6 |
Re:
Research/Valuation
|
|
EDTD
|
663 |
242K |
6 |
04/06/24 |
04/06/24 |
ASX - By Stock
|
663
|
242K
|
6
|
|
ASX - By Stock
|
CU6 |
Re:
Research/Valuation
|
|
EDTD
|
663 |
242K |
10 |
04/06/24 |
04/06/24 |
ASX - By Stock
|
663
|
242K
|
10
|
|
ASX - By Stock
|
RAC Biotech |
Re:
RAC - Charts & Price Action
|
|
EDTD
|
22K |
7.9M |
27 |
28/05/24 |
28/05/24 |
ASX - By Stock
|
22K
|
7.9M
|
27
|
|
ASX - By Stock
|
MSB |
Re:
MESO Nasdaq update
|
|
EDTD
|
5.9K |
2.9M |
4 |
21/05/24 |
21/05/24 |
ASX - By Stock
|
5.9K
|
2.9M
|
4
|
|
ASX - By Stock
|
MSB |
Re:
MESO Nasdaq update
|
|
EDTD
|
5.9K |
2.9M |
2 |
21/05/24 |
21/05/24 |
ASX - By Stock
|
5.9K
|
2.9M
|
2
|
|
ASX - By Stock
|
RAC Biotech |
Re:
Dr Tillett - The Accidental Biotech CEO
|
|
EDTD
|
7 |
3.4K |
23 |
20/05/24 |
20/05/24 |
ASX - By Stock
|
7
|
3.4K
|
23
|
|
ASX - By Stock
|
RAC Biotech |
Re:
Dr Tillett - The Accidental Biotech CEO
|
|
EDTD
|
7 |
3.4K |
18 |
20/05/24 |
20/05/24 |
ASX - By Stock
|
7
|
3.4K
|
18
|
|
ASX - By Stock
|
RAC |
Re:
Ann: RAC Investor Presentation May 2024
|
|
EDTD
|
55 |
17K |
15 |
17/05/24 |
17/05/24 |
ASX - By Stock
|
55
|
17K
|
15
|
|
ASX - By Stock
|
RAC |
Re:
[INTERVIEW] Breaking Barriers in Cancer Treatment: Race Oncology Pioneers a New Era with Bisantrene
|
|
EDTD
|
234 |
67K |
18 |
11/05/24 |
11/05/24 |
ASX - By Stock
|
234
|
67K
|
18
|
|
ASX - By Stock
|
LPD |
Re:
Ann: Completion of Entitlement Offer
|
|
EDTD
|
65 |
25K |
6 |
10/05/24 |
10/05/24 |
ASX - By Stock
|
65
|
25K
|
6
|
|
ASX - By Stock
|
LPD |
Re:
Ann: Completion of Entitlement Offer
|
|
EDTD
|
65 |
25K |
12 |
10/05/24 |
10/05/24 |
ASX - By Stock
|
65
|
25K
|
12
|
|
ASX - By Stock
|
LPD |
Re:
Ann: Completion of Entitlement Offer
|
|
EDTD
|
65 |
25K |
13 |
10/05/24 |
10/05/24 |
ASX - By Stock
|
65
|
25K
|
13
|
|
ASX - By Stock
|
LPD |
Re:
Ann: Completion of Entitlement Offer
|
|
EDTD
|
65 |
25K |
9 |
08/05/24 |
08/05/24 |
ASX - By Stock
|
65
|
25K
|
9
|
|
ASX - By Stock
|
RAC |
Re:
Cardioprotection thread
|
|
EDTD
|
906 |
275K |
2 |
08/05/24 |
08/05/24 |
ASX - By Stock
|
906
|
275K
|
2
|
|
ASX - By Stock
|
LPD |
Re:
Ann: Completion of Entitlement Offer
|
|
EDTD
|
65 |
25K |
25 |
08/05/24 |
08/05/24 |
ASX - By Stock
|
65
|
25K
|
25
|
|
ASX - By Stock
|
LPD |
Re:
Ann: Quarterly Activities/Appendix 5B Cash Flow Report
|
|
EDTD
|
46 |
18K |
29 |
07/05/24 |
07/05/24 |
ASX - By Stock
|
46
|
18K
|
29
|
|
ASX - By Stock
|
LPD |
Re:
Ann: Extension to Entitlement Offer Closing Date
|
|
EDTD
|
70 |
26K |
6 |
25/04/24 |
25/04/24 |
ASX - By Stock
|
70
|
26K
|
6
|
|
ASX - By Stock
|
LPD |
Re:
Ann: Directors & Key Managements Intention with Rights Offer
|
|
EDTD
|
57 |
20K |
18 |
08/04/24 |
08/04/24 |
ASX - By Stock
|
57
|
20K
|
18
|
|
ASX - By Stock
|
LPD |
Re:
Ann: Renounceable Entitlements Offer to Fund Arrangement of Phase
|
|
EDTD
|
96 |
42K |
24 |
04/04/24 |
04/04/24 |
ASX - By Stock
|
96
|
42K
|
24
|
|
ASX - By Stock
|
RAC |
Re:
Race options thread
|
|
EDTD
|
1.0K |
310K |
25 |
26/03/24 |
26/03/24 |
ASX - By Stock
|
1.0K
|
310K
|
25
|
|
ASX - By Stock
|
RAC |
Re:
Cardioprotection thread
|
|
EDTD
|
906 |
275K |
18 |
25/03/24 |
25/03/24 |
ASX - By Stock
|
906
|
275K
|
18
|
|
ASX - By Stock
|
RAC |
Re:
Cardioprotection thread
|
|
EDTD
|
906 |
275K |
20 |
25/03/24 |
25/03/24 |
ASX - By Stock
|
906
|
275K
|
20
|
|
ASX - By Stock
|
RAC |
Re:
Race options thread
|
|
EDTD
|
1.0K |
310K |
8 |
12/03/24 |
12/03/24 |
ASX - By Stock
|
1.0K
|
310K
|
8
|
|
ASX - By Stock
|
LPD |
Re:
Ann: Quarterly Activities/Appendix 5B Cash Flow Report
|
|
EDTD
|
426 |
133K |
12 |
12/03/24 |
12/03/24 |
ASX - By Stock
|
426
|
133K
|
12
|
|
ASX - By Stock
|
LPD |
Re:
Ann: Quarterly Activities/Appendix 5B Cash Flow Report
|
|
EDTD
|
426 |
133K |
9 |
12/03/24 |
12/03/24 |
ASX - By Stock
|
426
|
133K
|
9
|
|
ASX - By Stock
|
LPD |
Re:
Ann: Quarterly Activities/Appendix 5B Cash Flow Report
|
|
EDTD
|
426 |
133K |
31 |
10/03/24 |
10/03/24 |
ASX - By Stock
|
426
|
133K
|
31
|
|